Wonride M1 FORTE Dosage
In principle, the dosage of Wonride M1 FORTE is governed by the desired blood glucose level. The starting dose of Wonride M1 FORTE is 1 tab once a day before or with breakfast or first main meal. The dosage of Wonride M1 FORTE must be the lowest which is sufficient to achieve the desired metabolic control.
During treatment with Wonride M1 FORTE, glucose levels in blood and urine must be measured regularly. In addition, it is recommended that regular determinations of the proportion of glycated haemoglobin be carried out.
Mistakes eg, forgetting to take a dose, must never be corrected by subsequently taking a larger dose.
Measures for dealing with such mistakes (in particular, forgetting a dose or skipping a meal) or situations where a dose cannot be taken at the prescribed time must be discussed and agreed between physician and patient beforehand.
As an improvement in control of diabetes is, in itself, associated with higher insulin sensitivity, Glimepiride (Wonride M1 FORTE) requirements may fall as treatment proceeds. To avoid hypoglycaemia, timely dose reduction or cessation of Wonride M1 FORTE therapy must therefore be considered.
The highest recommended dose per day should be Glimepiride (Wonride M1 FORTE) 8 mg and Metformin (Wonride M1 FORTE) 2000 mg.
Daily doses of Glimepiride (Wonride M1 FORTE) of >6 mg are more effective only in a minority of patients.
In order to avoid hypoglycaemia, the starting dose of Wonride M1 FORTE should not exceed the daily doses of Glimepiride (Wonride M1 FORTE) or Metformin (Wonride M1 FORTE) already being taken.
When switching from combination therapy of Glimepiride (Wonride M1 FORTE) plus Metformin (Wonride M1 FORTE) as separate tablets, Wonride M1 FORTE should be administered on the basis of dosage currently being taken.
Titration: The daily dose should be titrated in increments of 1 tab only, corresponding to the lowest strength (in case various strengths are available).
Duration of Treatment: Treatment with Wonride M1 FORTE is normally a long-term therapy.
Administration: Wonride M1 FORTE should be administered once per day during breakfast or at the first main meal. Due to the sustained-release formulation, Wonride M1 FORTE must be swallowed whole and not crushed or chewed.
Metformin (Wonride M1 FORTE) HCl: Cationic Drugs: Amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim and vancomycin that are eliminated by renal tubular secretion, theoretically may cause an increase in Metformin (Wonride M1 FORTE) Cmax, whole blood concentrations and whole blood AUC by competing with Metformin (Wonride M1 FORTE) for common renal tubular transport system. Concomitant administration of Metformin (Wonride M1 FORTE) and cimetidine has been observed to result in reduced urinary Metformin (Wonride M1 FORTE) excretion and increased plasma and Metformin (Wonride M1 FORTE) concentrations.
Protein-Bound Drugs: Interaction of Metformin (Wonride M1 FORTE) and highly protein-bound drugs (eg, salicylates, sulfonamides, chloramphenicol, probenecid) is unlikely because Metformin (Wonride M1 FORTE) is negligibly bound to plasma proteins.
Antidiabetic Agents: Hypoglycemia may occur if used concomitantly with other antidiabetic agents such as sulfonylureas, glitazones or insulin.
Diuretics: Thiazide diuretics may exacerbate diabetes mellitus and may result in increased requirements of oral antidiabetic agents, including Metformin (Wonride M1 FORTE). Temporary loss of diabetic control, or secondary failure to the antidiabetic agent may also occur. Potassium-sparing diuretics may be considered as substitute.
Furosemide may increase Metformin (Wonride M1 FORTE) plasma and blood concentrations and blood AUC without significantly affecting Metformin (Wonride M1 FORTE) renal clearance.
Nifedipine: Concomitant administration may result in increased plasma concentration of Metformin (Wonride M1 FORTE) due to enhance absorption. Nifedipine may also increase urinary excretion of Metformin (Wonride M1 FORTE).
β-Adrenergic Blocking Agents: β-adrenergic blocking agents may impair glucose tolerance and mask the true frequency or severity of hypoglycemia, block hypoglycemia-induced tachycardia but not hypoglycemic sweating, delay the rate of recovery of blood glucose concentration following drug-induced hypoglycemia, and impair peripheral circulation. Use these drugs with caution in patients with type 2 diabetes.
Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE inhibitors (eg, captopril, enalapril, lisinopril, ramipril) may reduce fasting blood glucose concentrations. These drugs have also been associated with unexplained hypoglycemia in diabetic patients. Caution should be exercised when administering Metformin (Wonride M1 FORTE) together with ACE inhibitors to prevent severe hypoglycemia.
Clomiphene: Ovulatory response may be increased when clomiphene and Metformin (Wonride M1 FORTE) are used concomitantly in premenopausal patients with polycystic ovary syndrome.
Coumarin Anticoagulants: Metformin (Wonride M1 FORTE) may affect the pharmacokinetic properties of coumarin anticoagulants when administered concomitantly. An increase in prothrombin time may occur upon cessation of Metformin (Wonride M1 FORTE) therapy, with an increased risk of hemorrhage. Patients receiving phenprocoumon or other vitamin K anticoagulants should be carefully monitored.
Others: Drugs that may cause and exacerbate hyperglycemia over loss of glycemic control in patients with type 2 diabetes include corticosteroids, estrogen plus progesterone, oral contraceptives, phenytoin, thyroid products, sympathomimetics, phenothiazines, nicotinic acid, calcium-channel blockers and isoniazid. When such drugs are added to or withdrawn from therapy in patients receiving oral antidiabetic agents including Metformin (Wonride M1 FORTE), patients should be observed closely for evidence of altered glycemic control.
The pharmacokinetics of Metformin (Wonride M1 FORTE) and propanolol and ibuprofen were not affected when co-administered in a single dose.
Glimepiride (Wonride M1 FORTE): Aspirin: Concomitant use with aspirin results in an increased mean AUC and decreased mean Cmax of Glimepiride (Wonride M1 FORTE). However, there is no evidence of clinically significant adverse interactions with uncontrolled concurrent administration of aspirin and other salicylates.
H2 Receptor Antagonists: Co-administration of either cimetidine or ranitidine with a single oral dose of Glimepiride (Wonride M1 FORTE) did not significantly alter the absorption and disposition of Glimepiride (Wonride M1 FORTE) and no differences were seen in hypoglycemic symptomatology.
Propanolol: Concomitant administration of propanolol may result in significant increase in the Cmax, AUC and t½ of Glimepiride (Wonride M1 FORTE).
Miconazole: Potential interactions with oral hypoglycemic agents including Glimepiride (Wonride M1 FORTE) leading to severe hypoglycemia have been reported. It is not known whether this interaction also occurs with the IV, topical or vaginal preparations of miconazole.
Coumarin Anticoagulants: The pharmacodynamic response to warfarin may be potentiated or weakened by concomitant administration with Glimepiride (Wonride M1 FORTE). This may cause very small reductions in mean area under the prothrombin time (PT) curve and maximum PT values during Glimepiride (Wonride M1 FORTE) treatment.
Cytochrome P450: Glimepiride (Wonride M1 FORTE) is metabolized by cytochrome P450 2C9. This should be taken into account when Glimepiride (Wonride M1 FORTE) is co-administered with inducers (eg, rifampicin), inhibitors (eg, fluconazole) or substrates of CYP2C9 (eg, amiodarone, tolbutamide, diclofenac, ibuprofen, naproxen).
Alcohol: Acute and chronic alcohol intake may unpredictably potentiate or reduce the activity of Glimepiride (Wonride M1 FORTE).
Drugs that May Potentiate the Hypoglycemic Action of Glimepiride (Wonride M1 FORTE) and Other Sulfonylureas in Addition to Insulin and Other
Oral Antidiabetic Agents: Nonsteroidal anti-inflammatory drugs, sulfonamides, highly protein-bound drugs, chloramphenicol, coumarins/coumarin derivatives, probenecid, monoamine oxidase inhibitors, β-blockers, aminosalicylic acid, anabolic steroids, male sex hormones, azapropazone, chloramphenicol, clofibrate, cyclophosphamide, disopyramide, fenfluramine, fenyramidol, fibrates, fluoxetine, guanethidine, ifosfamide, oxpentifylline (high dose parenteral), oxyphenbutazone, phenylbutazone, probenecid, quinolones, sulfinpyrazone, tetracyclines, tritoqualine and trofosfamide.
β-blockers, clonidine, guanethidine and reserpine may mask the warning symptoms of a hypoglycemic attack during concomitant treatment with Glimepiride (Wonride M1 FORTE).
Drugs that Tend to Produce Hyperglycemia and May Lead to Loss of Glycemic Control when Co-Administered with Glimepiride (Wonride M1 FORTE): Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogen, progestogens, oral contraceptives, phenytoin, nicotinic acid (high doses), sympathomimetics, barbiturates, calcium channel blockers, diazoxide, glucagons, laxatives (protracted use) and isoniazid.
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology